Bernd Meibohm

This study evaluates replacing linezolid with spectinamide MBX-4888A in the Nix-TB regimen for tuberculosis in a mouse model, showing potential for reduced adverse effects.

This study shows that MBX-4888A, a spectinamide, shortens tuberculosis treatment in murine models by improving tissue distribution and working well with rifampin and pyrazinamide.

This study shows that aripiprazole, an atypical antipsychotic, worsens outcomes of disseminated Candida albicans infections in mice but has minimal effects on fungal growth or gene expression.

This study evaluates the biological activity of 60c, a next-generation colchicine-binding site inhibitor, showing improved potency and anti-metastatic effects in triple-negative breast cancer models.

This paper evaluates a modified BPaL regimen replacing linezolid with inhaled spectinamide 1599 for tuberculosis treatment, showing similar efficacy while avoiding linezolid-associated adverse events.